Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
AstraZeneca melds with Fusion in $2B radiopharma buyout
AstraZeneca is adding to the explosion of interest in radiopharmaceuticals, inking a $2 billion buyout to meld Fusion with its cancer unit.
Nick Paul Taylor
Mar 19, 2024 5:52am
Janux's shares jump 130% following T-cell engager data drop
Feb 27, 2024 10:35am
Pfizer funnels $15M into 3-year cancer care disparity initiative
Feb 5, 2024 10:00am
Next-gen PSA test maker Cleveland Dx rocks to $75M fundraising
Jan 29, 2024 11:07am
Approved IBS drug may help overcome prostate cancer resistance
Jan 22, 2024 11:00am
Deadline for Point investors as data meets Lilly's expectations
Dec 18, 2023 9:50am